Pembrolizumab demonstrated favorable long-term safety and antitumor activity in patients with advanced-stage melanoma, according to a pooled analysis of data from the KEYNOTE-001 study.
MRV Research
NYU Langone’s Laura and Isaac Perlmutter Cancer Center and Technion-Israel Institute of Technology Launch Global Research Initiative
Newswise — (New York, NY and Haifa, Israel, April 21, 2016) – Drug-carrying “nanoghosts” that battle melanoma and new treatments for malignant mesothelioma will be the focus of the first joint research projects led by NYU Langone Medical Center and the Technion-Israel Institute of Technology under a groundbreaking research initiative supported by noted philanthropists and NYU Langone Trustees Laura and Isaac Perlmutter.
Brisbane welcomes melanoma research centre
A world first melanoma research centre has opened in Brisbane, bringing together skin cancer experts from around the globe.
Aging Influences Melanoma Response to Therapies, but Antioxidants Could Provide Answer
The risk of developing cancer increases with age as accumulated damage to the cells and chronic inflammation arise over time. In a new study published in Nature, an international team of researchers led by The Wistar Institute demonstrated that aged melanoma cells behave in a different manner than younger cells, and that antioxidants could be a potential treatment strategy for older melanoma patients. The study is titled “sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.”